Sepranolone receives FDA IND approval in menstrual migraine
Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announces the FDA has approved the IND for its lead compound Sepranolone in menstrual migraine. It is an important confirmation of Sepranolone’s strong safety profile.“The FDA IND approval in menstrual migraine is an important validation of the strong safety profile of our compound and also has very positive implications for our upcoming larger clinical PMDD trials.” said Peter Nordkild, CEO of Asarina Pharma. “All preclinical and clinical data on Sepranolone, over 100 documents in all, were submitted to the FDA for review and